Kenton H. Zavitz
Chief Scientific Officer
United States of America
Kenton H. Zavitz, PhD, has more than 15 years of biotechnology and pharmaceutical experience, ranging from drug discovery and clinical development to pre-commercialization. In 1998, Zavitz joined Myriad Genetics, Inc. in Salt Lake City and worked for its subsidiary Myriad Pharmaceuticals, Inc. (later spun out as an independent public company and renamed Myrexis, Inc.). During his tenure with Myriad/Myrexis, Zavitz served as senior director of Clinical Affairs, chief scientist of the tarenflurbil clinical development program (an investigational drug for treating Alzheimer’s disease, developed through Phase 3), director of Neurodegeneration Therapeutics Discovery, director of Strategic In-licensing and Scientific Evaluation, and head of Drug Target Discovery and Validation. He has worked on the development of new drug products in various therapeutic areas, including Alzheimer’s disease, acute pain, HIV, oncology, and inflammatory diseases.
Biotechnology Pharmaceutics Drug Discovery and Clinical Development